Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Intensive Care Med ; 45(2): 211-222, 2019 02.
Article in English | MEDLINE | ID: mdl-30707246

ABSTRACT

PURPOSE: To test whether a multicomponent intervention would increase the use of low molecular weight heparin (LMWH) over unfractionated heparin (UFH) for venous thromboembolism (VTE) prophylaxis in critically ill patients and change patient outcomes and healthcare utilization. METHODS: Controlled pre-post trial of 12,342 adults admitted to 11 ICUs (five intervention, six control) May 1, 2015 to April 30, 2017 with no contraindication to pharmacological prophylaxis and an ICU stay longer than 24 h. Models were developed to examine temporal changes in ICU VTE prophylaxis (primary outcome), VTE, major bleeding, heparin-induced thrombocytopenia (HIT), death and hospital costs. RESULTS: The use of LMWH increased from 45.9% to 78.3% of patient days in the intervention group and from 37.9% to 53.3% in the control group, an absolute increase difference of 17.0% (32.4% vs. 15.4%, p = 0.001). Changes in the administration of UFH were inversely related to those of LMWH. There were no significant differences in the adjusted odds of VTE (ratio of odds ratios [rOR] 1.13, 95% CI 0.51-2.46) or major bleeding (rOR 1.22, 95% CI 0.97-1.54) post-implementation of the intervention (compared to pre-implementation) between the intervention group and the control group. HIT was uncommon in both groups (n = 20 patients). There were no significant changes for ICU and hospital mortality, length of stay and costs. Results were similar when stratified according to reason for ICU admission, patient weight and kidney function. CONCLUSIONS: A multicomponent intervention changed practice, but not clinical and economic outcomes. The benefit of implementing LMWH for VTE prophylaxis under real-world conditions is uncertain.


Subject(s)
Heparin, Low-Molecular-Weight/standards , Pre-Exposure Prophylaxis/standards , Venous Thromboembolism/prevention & control , Aged , Anticoagulants/pharmacology , Anticoagulants/standards , Anticoagulants/therapeutic use , Critical Illness/therapy , Evidence-Based Practice/methods , Female , Heparin, Low-Molecular-Weight/pharmacology , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Implementation Science , Intensive Care Units/organization & administration , Intensive Care Units/statistics & numerical data , Interrupted Time Series Analysis , Length of Stay/statistics & numerical data , Logistic Models , Male , Middle Aged , Odds Ratio , Outcome Assessment, Health Care/methods , Practice Patterns, Physicians' , Pre-Exposure Prophylaxis/methods , Registries/statistics & numerical data , Retrospective Studies , Venous Thromboembolism/drug therapy
2.
J Crit Care ; 50: 111-117, 2019 04.
Article in English | MEDLINE | ID: mdl-30529419

ABSTRACT

PURPOSE: This study evaluated a complex initiative to increase evidence-based use of low molecular weight heparin for venous thromboembolism prophylaxis among adult medical-surgical ICU patients. MATERIALS AND METHODS: This study included: quantitative survey and interviews. Participants were healthcare providers within four ICUs. Surveys collected knowledge of evidence underpinning best practice, exposure to the implementation strategies and their perceived utility, and recommendations. The interview expanded on survey topics. Descriptive statistics summarized the data and chi-squared tests were used to compare groups. Qualitative data were analyzed using a blended deductive and inductive coding approach. RESULTS: Providers had good knowledge of the evidence (range = 58% to 94%). Pharmacist-to-physician reminders (80%), other reminders (50%), and local guidelines (50%) were the most commonly observed strategies. Local champions (76%), on-site education (74%), and computerized decision support system (69%) were perceived to be most helpful. Interviews elicited five themes: provider roles, perceptions of the implementation strategies, facilitators and barriers to uptake of best practice, and recommendations. Assessment of the implementation strategies varied by professional group. CONCLUSIONS: The findings of this process evaluation identified implementation strategies that can improve the use of evidence-informed practices, help interpret outcomes in the context of interventions and guide future quality improvement initiatives.


Subject(s)
Anticoagulants/therapeutic use , Health Knowledge, Attitudes, Practice , Heparin, Low-Molecular-Weight/therapeutic use , Venous Thromboembolism/drug therapy , Adult , Critical Illness/therapy , Cross-Sectional Studies , Decision Support Systems, Clinical , Female , Humans , Intensive Care Units , Male , Middle Aged , Process Assessment, Health Care , Quality Improvement
3.
Can J Infect Dis Med Microbiol ; 2016: 3702625, 2016.
Article in English | MEDLINE | ID: mdl-27525016

ABSTRACT

This retrospective cohort study describes the patterns of antibiotic use for the treatment of ventilator-associated pneumonia (VAP) in the Calgary Zone of Alberta Health Services. Timing, appropriateness, and duration of antibiotics were evaluated in two hundred consecutive cases of VAP derived from 4 adult intensive care units (ICU). Antibiotic therapy was initiated in less than 24 hours from VAP diagnosis in 83% of cases. Although most patients (89%) received empiric therapy that demonstrated in vitro sensitivity to the identified pathogens, only 24% of cases were congruent with the 2008 Association of Medical Microbiology and Infectious Disease (AMMI) guidelines. Both ICU (p = 0.001) and hospital (p = 0.015) mortality were significantly lower and there was a trend for shorter ICU length of stay (p = 0.051) in patients who received appropriate versus inappropriate initial antibiotics. There were no outcome differences related to compliance with AMMI guidelines. This exploratory study provides insight into the use of antimicrobials for the treatment of VAP in a large Canadian health region. The discordance between the assessments of appropriateness of empiric therapy based on recovered pathogens versus AMMI guidelines is notable, emphasizing the importance of using as much as possible local microbiologic and antimicrobial resistance data.

SELECTION OF CITATIONS
SEARCH DETAIL